• <nav id="ycwek"></nav>
  • <menu id="ycwek"><tt id="ycwek"></tt></menu>
    <nav id="ycwek"><strong id="ycwek"></strong></nav>
  • Market Overview

    What Pfizer's Coronavirus Vaccine Data Means For Moderna

    What Pfizer's Coronavirus Vaccine Data Means For Moderna

    Moderna Inc (NASDAQ: MRNA) shares were advancing strongly Monday after a rival vaccine developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) showed efficacy in a late-stage study.

    High Bar For Moderna To Clear: The 90% vaccine efficacy demonstrated by Pfizer and BioNTech sets an extremely high bar for Moderna, SVB Leerink analyst Mani Foroohar said in a Monday note. 

    The data announcement — and uptick in COVID-19 cases — removes any concerns surrounding a delay in the number of cases needed to hit the first interim point, the analyst said. 

    Moderna is on track for a first interim readout this month, he said.

    "We anticipate MRNA shares to be up materially today with this positive read across, given the similar mechanism of action for both vaccines, but see risk/reward into MRNA's own data release as skewed to the downside given cross-trial comparisons to PFE/BNTX's (excellent) data released today," Foroohar said. 

    Related Link: The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions

    Fauci Fuels Hopes For 2 Vaccines: While applauding Pfizer for the positive data, NIAID Director Anthony Fauci seemed to suggest Moderna's late-stage trial may also have a similar outcome.

    "The results are really quite good, I mean extraordinary," Fauci said, according to The Independent

    Pfizer's results might bode well for the vaccine being developed by Moderna in collaboration with the NIAID, as both use similar technology, Fauci reportedly said.

    Pfizer, BioNTech and Moderna, are developing mRNA vaccines, which work by introducing an mRNA sequence coded for a disease-specific antigen. Once produced within the body, the antigen is recognized by the immune system, preparing it to fight the virus.

    MRNA Price Action: At last check, Moderna shares were advancing 7.97% to $78.23. 

    Related Link: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

    Latest Ratings for MRNA

    Dec 2020Argus ResearchMaintainsBuy
    Nov 2020SVB LeerinkMaintainsUnderperform
    Nov 2020Wells FargoInitiates Coverage OnEqual-Weight

    View More Analyst Ratings for MRNA
    View the Latest Analyst Ratings


    Related Articles (MRNA)

    View Comments and Join the Discussion!

    Posted-In: Coronavirus Covid-19Analyst Color Biotech Health Care Top Stories Analyst Ratings General Best of Benzinga

    Latest Ratings

    ESTCCanaccord GenuityMaintains150.0
    AVAVCanaccord GenuityMaintains98.0
    OKTACanaccord GenuityMaintains250.0
    SNOWCanaccord GenuityMaintains275.0
    RCMSVB LeerinkMaintains26.0
    View the Latest Analytics Ratings
    Don't Miss Any Updates!
    News Directly in Your Inbox
    Subscribe to:
    Benzinga Premarket Activity
    Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Fintech Focus
    A daily collection of all things fintech, interesting developments and market updates.
    Thank You

    Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com